top of page

PIPELINE
Developing innovative treatments
for rare CNS disorders
Our programs target rare CNS and neurodevelopmental disorders through novel mechanisms of action.

pipeline march 2025.png

LEAD PROGRAMS

CSTI-500 is a triple monoamine reuptake inhibitor (TRI) that modulates serotonin, dopamine, and norepinephrine by inhibiting their respective transporters (SERT, DAT, and NET). These neurotransmitters are key regulators of behavior, feeding, and mood control.

Research in both human and animal models indicates that Prader-Willi Syndrome (PWS) is associated with deficiencies in serotonin, dopamine, and norepinephrine, contributing to feeding and behavioral dysregulation. By simultaneously modulating these three neurotransmitters, CSTI-500 has the potential to help address hyperphagia, anxiety, irritability, temper outbursts, and other neuropsychiatric challenges associated with PWS. Clinical efficacy and safety of CSTI-500 in this context are still being investigated.

CSTI-500: A Phase 2-Ready, Tunable Triple Monoamine Reuptake Inhibitor

An innovative therapy aiming to comprehensively address hyperphagia and other neurobehavioral challenges in Prader-Willi Syndrome.

CSTI-100 / HBS-102

MCHR1 antagonist for the treatment of rare neurological disorders.

bottom of page